Mannan (50-500 ppm; p.o., dietary; daily; 4 weeks) reduces Aflatoxin B1 (HY-N6615)-induced toxicity in mice, as evidenced by increased body weight, decreased rate of normochromatic erythrocytes with micronuclei, and decreased rate of sister chromatid exchanges[2].
Mannan (50-100 mg/kg; i.p.; 2-5 times) reduces serum levels of low-density lipoprotein (LDL), cholesterol, and triglycerides in mice with acute dyslipidemia induced by poloxamer 407 (HY-D1005)[4].
| Animal Model: | Male CBA/Lac mice (2.5-3-month-old, weighing 22-25 g), acute lipemia induced by poloxamer 407 model[4] |
| Dosage: | 50 mg/kg, 100 mg/kg |
| Administration: | Intraperitoneal injection, 5 times at 50 mg/kg every other day or 2 times at 100 mg/kg with 1-day interval |
| Result: | Reduced the levels of triglyceride, atherogenic LDL, and total cholesterol in the serum at 50 mg/kg and 100 mg/kg.
Decreased the triglyceride concentration in the liver.
Increased the lability of lysosomal membranes in the liver and elevated the serum activity of chitotriosidase, a marker of macrophage activation.
|
